Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)

Inclusion Criteria * Histologic or cytologic diagnosis with unresectable or metastatic HCC * Child Pugh Class A * ECOG performance status 0-1 * Adequate hematologic, hepatic, and renal function Exclusion Criteria * Prior systemic (administered intravenously or orally rather than locoregionally) treatment for HCC * Prior local therapy (including liver-directed therapy) within 4 weeks from entry * Untreated brain or meningeal metastases * Current treatment on another clinical trial * Pregnancy or breastfeeding